한글목차

호흡기 생물학적 제제 시장 규모는 최근 급성장하고 있습니다. 2025년 74억 1,000만 달러에서 2026년에는 86억 1,000만 달러에 이르고, CAGR 16.3%의 성장이 전망되고 있습니다. 지난 몇 년간 성장 요인으로는 기존 흡입기의 한계, 중증 천식 환자 증가, 바이오 의약품 치료제의 승인 확대, 면역학 연구의 발전, 전문 클리닉의 확대 등을 꼽을 수 있습니다.

호흡기 바이오로직스 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 156억 6,000만 달러에 이르고, CAGR은 16.1%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 정밀 호흡기 의료의 발전, 생물학적 제제 파이프라인의 확대, 의료비 지출 증가, 상환 정책 개선, 중증 호흡기 질환의 미충족 수요 등을 꼽을 수 있습니다. 주요 동향으로는 표적 생물학적 치료제의 도입 확대, 중증 천식 치료의 확대, 바이오마커에 기반한 환자 선택의 발전, 주사형 호흡기 약물의 사용 증가, 지속형 생물학적 제제로의 전환이 예측됩니다.

대기오염의 급격한 증가는 향후 몇 년 동안 호흡기 생물학 시장을 견인할 것으로 예측됩니다. 대기오염이란 지구의 대기 중에 존재하는 가스, 입자상 물질, 생물학적 물질 등의 유해물질을 말하며, 인간의 건강과 환경에 악영향을 미칩니다. 산업화와 도시화의 진전에 따라 공장, 차량, 건설현장의 오염물질 배출량이 증가함에 따라 대기오염이 심각해지고 있습니다. 호흡기 바이오로직스는 대기오염 물질에 노출된 사람들의 염증을 완화하고 폐 기능을 개선하는 정밀 치료를 통해 대기오염이 건강에 미치는 영향에 대응합니다. 예를 들어, 2025년 1월 미국 정부 기관인 환경보호청(EPA)은 2023년 미국이 6,600만 톤 이상의 오염물질을 대기 중으로 배출했다고 보고했습니다. 이처럼 심각해지는 대기오염이 호흡기 바이오로직스 시장 확대를 견인하고 있습니다.

호흡기 생물학 시장의 주요 기업들은 만성 호흡기 질환에 대한 표적 면역 요법을 포함한 최첨단 생물학적 치료법 개발에 우선순위를 두고 있으며, 염증을 억제하고 폐 기능을 개선하는 정밀한 개입을 제공합니다. 만성 호흡기 질환을 위한 표적 면역 치료는 지속성 폐질환의 부종과 호흡곤란을 완화하기 위해 신체의 면역반응을 조절하여 작용합니다. 예를 들어, 2024년 9월 프랑스에 본사를 둔 제약사 사노피(Sanofi S.A.)는 미국 식품의약국(FDA)이 호산구성 프로파일을 가진 조절되지 않는 만성폐쇄성폐질환(COPD) 성인 환자의 추가 유지요법으로 듀픽센트(Dupixent, 듀피루맙)를 승인했다고 발표했습니다. 발표했습니다. 이번 승인으로 듀픽센트는 미국에서 이 특정 COPD 환자군을 위해 승인된 최초의 생물학적 제제로서의 지위를 확보했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Respiratory biologics are precision therapies from living organisms that target specific immune molecules like interleukins (IL-4, IL-5, IL-13) or IgE to curb inflammation and boost breathing in chronic respiratory diseases; they're typically prescribed for severe, uncontrolled cases unresponsive to standard treatments such as inhaled corticosteroids and bronchodilators.

Respiratory biologics primarily target diseases like asthma, chronic rhinosinusitis, and hypereosinophilic syndrome. Asthma represents a chronic inflammatory condition of the airways, leading to breathing difficulties, wheezing, and coughing from narrowed airways and heightened responsiveness. Available administration routes encompass intravenous and subcutaneous methods, with distribution through channels including hospitals, specialty clinics, retail pharmacies, and mail-order pharmacies.

Tariffs have affected the respiratory biologics market by increasing the cost of imported biologic drug substances, cell culture materials, and cold-chain packaging components. These impacts have been most pronounced in monoclonal antibody therapies, particularly in north america and europe where biologic manufacturing inputs are globally sourced. Asia-pacific producers have faced cold-chain logistics cost pressures. However, tariffs have encouraged regional biologics manufacturing and local fill-finish capacity expansion, supporting supply continuity.

The respiratory biologics market research report is one of a series of new reports from The Business Research Company that provides respiratory biologics market statistics, including respiratory biologics industry global market size, regional shares, competitors with a respiratory biologics market share, detailed respiratory biologics market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory biologics industry. This respiratory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory biologics market size has grown rapidly in recent years. It will grow from $7.41 billion in 2025 to $8.61 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to limitations of conventional inhalers, rising severe asthma cases, biologic therapy approvals, improved immunology research, specialty clinic expansion.

The respiratory biologics market size is expected to see rapid growth in the next few years. It will grow to $15.66 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to precision respiratory medicine growth, expansion of biologics pipelines, rising healthcare spending, improved reimbursement policies, unmet needs in severe respiratory disease. Major trends in the forecast period include rising adoption of targeted biologic therapies, expansion of severe asthma treatments, growth of biomarker-based patient selection, increasing use of injectable respiratory drugs, shift toward long-acting biologic agents.

The surge in air pollution is projected to boost the respiratory biologics market in the years ahead. Air pollution involves harmful substances like gases, particulate matter, and biological agents in the Earth's atmosphere, adversely affecting human health and the environment. It is escalating due to expanding industrialization and urbanization, which increase pollutant emissions from factories, vehicles, and construction. Respiratory biologics address the health impacts of air pollution through precise therapies that alleviate inflammation and enhance lung function for those exposed to airborne contaminants. For instance, in January 2025, the Environmental Protection Agency-a US government agency-reported that the United States emitted more than 66 million tons of pollutants into the atmosphere in 2023. Thus, escalating air pollution is fueling expansion in the respiratory biologics market.

Major companies in the respiratory biologics market are prioritizing the development of cutting-edge biologic therapies, including targeted immune treatments for chronic respiratory conditions, to deliver precise interventions that curb inflammation and enhance lung performance. Targeted immune therapies for chronic respiratory diseases work by modulating the body's immune response to alleviate swelling and breathing difficulties in persistent lung disorders. For example, in September 2024, Sanofi S.A., a pharmaceutical firm headquartered in France, revealed that the US Food and Drug Administration (FDA) had approved Dupixent (dupilumab) as an additional maintenance treatment for adults suffering from uncontrolled chronic obstructive pulmonary disease (COPD) with an eosinophilic profile. This approval represented a key achievement, positioning Dupixent as the inaugural biologic drug cleared in the US for this particular subset of COPD patients.

In February 2024, GlaxoSmithKline plc, a pharmaceutical firm headquartered in the UK, purchased Aiolos Bio for an undisclosed sum. Through this deal, GSK seeks to bolster its respiratory and immunology lineup by gaining access to Aiolos Bio's cutting-edge therapies targeting inflammatory and immune-mediated conditions. Aiolos Bio, based in the US, specializes in creating biologic treatments for respiratory and inflammatory disorders.

Major companies operating in the respiratory biologics market are Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

North America was the largest region in the respiratory biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the respiratory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory biologics market consists of sales of monoclonal antibodies (mAbs), interleukin inhibitors, and immunomodulators. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Biologics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses respiratory biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The respiratory biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Disease Indication: Asthma; Chronic Rhinosinasitis; Hypereosinophilic Syndrome
• 2) By Route Of Administration: Intravenous; Subcutaneous
• 3) By Sales Channel: Hospitals; Specialty Clinics; Retail Pharmacies; Mail Order Pharmacies
• Subsegments:
• 1) By Asthma: Severe Eosinophilic Asthma; Allergic Asthma; Non-Allergic Asthma
• 2) By Chronic Rhinosinasitis: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps; Chronic Rhinosinusitis without Nasal Polyps
• 3) By Hypereosinophilic Syndrome (HES): Idiopathic HES; Lymphocytic Variant HES; Myeloproliferative HES
• Companies Mentioned: Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline plc; Regeneron Pharmaceuticals Inc.; Novartis AG; F. Hoffmann-La Roche Ltd.; Amgen Inc.; Swedish Orphan Biovitrum AB; Teva Pharmaceutical Industries Ltd.; AbbVie Inc.; Pfizer Inc.; Merck & Co. Inc.; Bristol Myers Squibb Company; Johnson & Johnson; Boehringer Ingelheim International GmbH; Biogen Inc.; Vertex Pharmaceuticals Incorporated; Glenmark Pharmaceuticals Ltd.; Kiniksa Pharmaceuticals Ltd.; Pieris Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Respiratory Biologics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Respiratory Biologics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Respiratory Biologics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Respiratory Biologics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Targeted Biologic Therapies
  • 4.2.2 Expansion Of Severe Asthma Treatments
  • 4.2.3 Growth Of Biomarker-Based Patient Selection
  • 4.2.4 Increasing Use Of Injectable Respiratory Drugs
  • 4.2.5 Shift Toward Long-Acting Biologic Agents

5. Respiratory Biologics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Pulmonology Clinics
• 5.3 Allergy And Immunology Clinics
• 5.4 Specialty Pharmacies
• 5.5 Home Infusion Centers

6. Respiratory Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Respiratory Biologics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Respiratory Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Respiratory Biologics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Respiratory Biologics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Respiratory Biologics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Respiratory Biologics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Respiratory Biologics Market Segmentation

• 9.1. Global Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome
• 9.2. Global Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous, Subcuteneous
• 9.3. Global Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies
• 9.4. Global Respiratory Biologics Market, Sub-Segmentation Of Asthma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma
• 9.5. Global Respiratory Biologics Market, Sub-Segmentation Of Chronic Rhinosinusitis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps
• 9.6. Global Respiratory Biologics Market, Sub-Segmentation Of Hypereosinophilic Syndrome (HES), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

10. Respiratory Biologics Market Regional And Country Analysis

• 10.1. Global Respiratory Biologics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Respiratory Biologics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Respiratory Biologics Market

• 11.1. Asia-Pacific Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Respiratory Biologics Market

• 12.1. China Respiratory Biologics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Respiratory Biologics Market

• 13.1. India Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Respiratory Biologics Market

• 14.1. Japan Respiratory Biologics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Respiratory Biologics Market

• 15.1. Australia Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Respiratory Biologics Market

• 16.1. Indonesia Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Respiratory Biologics Market

• 17.1. South Korea Respiratory Biologics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Respiratory Biologics Market

• 18.1. Taiwan Respiratory Biologics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Respiratory Biologics Market

• 19.1. South East Asia Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Respiratory Biologics Market

• 20.1. Western Europe Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Respiratory Biologics Market

• 21.1. UK Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Respiratory Biologics Market

• 22.1. Germany Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Respiratory Biologics Market

• 23.1. France Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Respiratory Biologics Market

• 24.1. Italy Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Respiratory Biologics Market

• 25.1. Spain Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Respiratory Biologics Market

• 26.1. Eastern Europe Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Respiratory Biologics Market

• 27.1. Russia Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Respiratory Biologics Market

• 28.1. North America Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Respiratory Biologics Market

• 29.1. USA Respiratory Biologics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Respiratory Biologics Market

• 30.1. Canada Respiratory Biologics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Respiratory Biologics Market

• 31.1. South America Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Respiratory Biologics Market

• 32.1. Brazil Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Respiratory Biologics Market

• 33.1. Middle East Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Respiratory Biologics Market

• 34.1. Africa Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Respiratory Biologics Market, Segmentation By Disease Indication, Segmentation By Route Of Administration, Segmentation By Sales Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Respiratory Biologics Market Regulatory and Investment Landscape

36. Respiratory Biologics Market Competitive Landscape And Company Profiles

• 36.1. Respiratory Biologics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Respiratory Biologics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Respiratory Biologics Market Company Profiles
  • 36.3.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Respiratory Biologics Market Other Major And Innovative Companies

• F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

38. Global Respiratory Biologics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Respiratory Biologics Market

40. Respiratory Biologics Market High Potential Countries, Segments and Strategies

• 40.1 Respiratory Biologics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Respiratory Biologics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Respiratory Biologics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer